



Gamma Knife Radiosurgery for Intracranial Hemangioblastomas

Danilo Silva MD; Matthew Mark Grabowski MD; Mithun Gururaj Sattur MCh; Biji Bahuleyan MD; Gene H. Barnett MD; Lilyana Angelov MD; Michael A. Vogelbaum MD, PhD; Samuel T. Chao MD; John H. Suh; Alireza M Mohammadi MD

Departments of Neurosurgery and Radiation Oncology
Rose Ella Burkhardt Brain Tumor Center
Cleveland Clinic, OH, USA



Introduction

Gamma knife radiosurgery (GKRS) has become an option for tumor control in hemangioblastoma as both an upfront treatment (especially for non-accessible tumors), and for recurrent and/or residual cases that failed surgical resection. It has the capability of treating multiple lesions in one single session in a minimally invasive way, preventing multiple surgical procedures. The objective of this study was to analyze clinical outcome and tumor control rates.

Methods

We conducted a retrospective chart review of 12 patients with a total of 20 intracranial hemangioblastomas treated with GKRS at the Cleveland Clinic from May 1998 until December 2014. Median age at time of GKRS was 51.7 years (34-80). Four patients had multiple lesions. Four patients had von Hippel-Lindau disease, with a combined total of 11 tumors. The majority of tumors were solid (18) and located in the cerebellum (19). GKRS was employed as the primary treatment in 9 lesions, and utilized to treat recurrence in the other 11 tumors. Median prescription margin dose was 24Gy (14-25).

Learning Objectives

After conclusion of this study, one should be able to:

- 1)Identify the treatment options for intracranial hemangioblastomas;
- 2)Recognize gamma knife radiosurgery as an effective and safe treatment option for intracranial hemangioblastomas;
- 3)Interpret the situations in which radiosurgery plays an important role as a treatment option.

Results

Median follow up was 64 months (2-184). Median tumor volume pre-GKRS was 946 mm3 (79-15970), while median tumor volume post-GKRS was 356 mm3 (30-5404). This equated to a median percentage reduction in tumor volume of 46%, with 17 tumors (85%) being stable or decreased in size, while the remaining 3 tumors (15%) showed evidence of radiographic progression at last follow up. Tumor control rates were 100% at 1 year, 90% at 3 years, and 85% at 5 years, using the Kaplan–Meier method. Two patients experienced complication (hydrocephalus and radiation necrosis, respectively). There were no statistically significant univariate predictors of progression identified, although there was a trend towards successful tumor control in solid tumors (p=0.07).

References

- 1- Kano H, Niranjan A, Mongia S, Kondziolka D, Flickinger J, Lunsford LD: The role of stereotactic radiosurgery for intracranial hemangioblastomas. Neurosurgery 63:443–451, 2008.
- 2- Kano H, Shuto T, Iwai Y, Sheehan J, Yamamoto M, McBride HL, Sato M, Serizawa T, Yomo S, Moriki A, Kohda Y, Young B, Suzuki S, Kenai H, Duma C, Kikuchi Y, Mathieu D, Akabane A, Nagano O, Kondziolka D, Lunsford LD: Stereotactic radiosurgery for intracranial hemangioblastomas: a retrospective international outcome study. J Neurosurg. 2015 Mar 27:1-10.
- 3- Sayer F, Nguyen J, Starke R, Yen CP, Sheehan JP: Gamma knife radiosurgery for intracranial hemangioblastomas - Outcome at 3 Years. World neurosurgery 75: 99-105, 2011.
- 4-AsthaGiri AR , Mehta GU, Zach L, Li X, Butman JA, Camphausen KA, Lonser RR: Prospective evaluation of radiosurgery for hemangioblastomas in von Hippel-Lindau disease. Neuro-Oncol 12:80-86, 2010

Conclusions

GKRS is an effective and safe option for treating intracranial hemangioblastomas with favorable tumor control rates.

